Indaptus Therapeutics (INDP)

The company’s patented technology uses attenuated and killed, non-pathogenic Gram-negative bacterial strains. These bacteria are engineered or selected to retain immunologic activity while reducing the risks associated with live pathogenic organisms or excessive inflammatory reactions. By presenting a package of immune-activating signals, the approach aims to prime or activate a range of immune cells that may help the body recognise and attack tumours or respond to viral threats.

Indaptus’ lead candidate, Decoy20, is being developed for patients with solid tumours. Solid tumour oncology is a highly competitive and scientifically challenging field, but it also represents a major area of unmet need, particularly for patients who do not respond adequately to existing immunotherapies such as checkpoint inhibitors. The company’s work is therefore positioned as a differentiated attempt to broaden immune activation in cancer treatment.

As a clinical biotechnology business, Indaptus does not resemble a commercial pharmaceutical company with diversified product revenue. Its value depends heavily on trial progress, safety data, regulatory interactions, manufacturing execution, and the ability to secure financing or partnerships. For investors, the stock represents a high-risk, research-driven exposure to novel immuno-oncology and immune-modulation science.